scholarly journals Endovascular treatment of postinfarction ventricular septal defects

2016 ◽  
Vol 20 (2) ◽  
pp. 80
Author(s):  
D. A. Khelimskiy ◽  
O. V. Krestyaninov ◽  
A. G. Osiev ◽  
A. A. Shermuk ◽  
D. S. Grankin ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Transcatheter Closure ◽  
Clinical Status ◽  
Multiple Organ ◽  
Defect Size ◽  
Ventricular Septal Defects ◽  
Septal Defects ◽  
Device Implantation ◽  
Implanted Devices

<p><strong>Aim:</strong> The study was designed to evaluate the possibility and safety of transcatheter closure of postinfarction ventricular septal defects in different periods after acute myocardial infarction.<br /><strong>Methods:</strong> Over a period from 2010 to 2015 15 patients (11 females and 4 males) underwent transcatheter closure of postinfarction ventricular septal defects. The time from the onset of infarction to the intervention varied between 1 day and 6 months (mean 10.9 weeks). Three patients were treated in an acute phase of infarction (two weeks or less). The defect size ranged 7-24 mm (mean 13.5 mm), while the implanted devices sized 12-34 mm (mean 22.8 mm). The procedure and screening time amounted to 67-170 (mean 115.3) and 14-78 (mean 32.5) minutes respectively.<br /><strong>Results:</strong> A successful device implantation occurred in all but one patient whose occluder was dislodged. This patient later underwent successful surgical VSD closure. Occluder implantation failed to improve the clinical status of two patients in a critical condition. They developed multiple organ failure and died at 2 and 9 days after the procedure.<br /><strong>Conclusion:</strong> Transcatheter closure of postinfarction ventricular septal defects may be an alternative to surgery in patients with suitable anatomy and multiple comorbidities. However, in-hospital mortality remains high, even after successful occluder implantation.</p>

scholarly journals Transcatheter closure of muscular ventricular septal defects using the Cardi-O-Fix plug

2021 ◽  
pp. 1-4
Author(s):  
Zhisong Chen ◽  
Zhuo Yu ◽  
Li Su ◽  
Huasheng Zhang ◽  
Wei Hu
Keyword(s):  
Transcatheter Closure ◽  
Left Ventricular ◽  
Defect Size ◽  
Ventricular Septal Defects ◽  
Chordae Tendineae ◽  
Effective Treatment Option ◽  
Septal Defects ◽  
Device Implantation ◽  
The Right

Abstract Objective: The aim of this study was to evaluate the safety and efficacy of the Cardi-O-Fix plug used for the treatment of muscular ventricular septal defects. Methods: We retrospectively reviewed the medical records of five patients with muscular ventricular septal defects who underwent transcatheter closure using the Cardi-O-Fix Plug, from November 2017 to August 2019. The median age was 5.1 years (range: 3.2–6.5). Their median body weight was 18.1 kg (range: 13.4–21.8). All the patients underwent detailed two-dimensional Doppler and colour flow imaging by transthoracic echocardiography. The left ventricular median defect size of the muscular ventricular septal defects was 5.6 mm (range: 5.3–7.0). The right ventricular median defect size of the muscular ventricular septal defects was 3.9 mm (range: 3.3–4.7). All the procedures were performed on beating hearts. Results: All the patients underwent successful device implantation with no displacement or detachment, they have complete echocardiographic closure at the 1-year follow-up. There were no occluder-related arrhythmia, chordae tendineae rupture, tricuspid insufficiency, aortic regurgitation, haemolysis, or embolisation. Conclusions: Application of the Cardi-O-Fix plug appears to be a feasible, safe, and effective treatment option for patients with muscular ventricular septal defects. Longer follow-up periods are warranted to prove the conclusion for long-term outcomes.

Transcatheter Closure of Muscular Ventricular Septal Defects in Two Patients After Myocardial Infarction

2001 ◽  
Vol 14 (2) ◽  
pp. 219-222 ◽  
Author(s):  
A. PARSI ◽  
L. BRUCH ◽  
G. SZURAWITZKI ◽  
C. BOOSFELDT ◽  
M. O. GRAD ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Transcatheter Closure ◽  
Ventricular Septal Defects ◽  
Septal Defects

Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer Vascular Plug-II

2015 ◽  
Vol 26 (6) ◽  
pp. 1194-1201 ◽  
Author(s):  
Nancy Hua ◽  
Paolo Aquino ◽  
Carl Y. Owada
Keyword(s):  
Transcatheter Closure ◽  
Left Ventricular ◽  
Defect Size ◽  
Amplatzer Vascular Plug ◽  
Ventricular Septal Defects ◽  
Vascular Plug ◽  
Effective Treatment Option ◽  
Septal Defects ◽  
Amplatzer Vascular Plug Ii

AbstractObjectiveThe aim of this study was to evaluate the safety and efficacy of the Amplatzer Vascular Plug-II used for the closure of perimembranous ventricular septal defects.BackgroundThere are no FDA-approved transcatheter devices for the closure of perimembranous ventricular septal defects. Several studies have reported on the use of various devices either off-label or under clinical trial protocols. However these reports have described significant adverse events including residual shunts, complete heart block, arrhythmia, and new valve regurgitations. Thus far, no study on the Amplatzer Vascular Plug-II has been reported.MethodsWe conducted a 4-year retrospective chart review from August, 2010 to August, 2014, of patients with perimembranous ventricular septal defects associated with ventricular septal aneurysm who underwent transcatheter closure using the Amplatzer Vascular Plug-II.ResultsA total of 16 patients underwent Amplatzer Vascular Plug-II transcatheter closure of their perimembranous ventricular septal defects. The median age was 2.56 years (range: 0.5–27.3). Their median weight was 13.0 kg (range: 6.9–71.6). The left ventricular median defect size was 9.3 mm (range: 5.9–14.4). The right ventricular median defect size was 3.6 mm (range: 2.3–5.8). All the patients underwent successful device implantation with 83% of the patients having complete echocardiographic closure at the 1-year follow-up; however, one procedure was complicated by early device embolisation. The device was successfully retrieved and replaced with a larger device. There were no device-related outflow tract obstructions, rhythm abnormalities, or haemolysis.ConclusionApplication of the Amplatzer Vascular Plug-II for closure of perimembranous ventricular septal defects appears to be a safe and effective treatment option. Prospective clinical trials and longer follow-up periods are warranted.

Transcatheter closure of doubly committed subarterial ventricular septal defects with the Amplatzer ductal occluder: initial experience

2019 ◽  
Vol 29 (5) ◽  
pp. 570-575
Author(s):  
Yu Huang ◽  
Xiaoping Yan ◽  
Linxiang Lu ◽  
Jun Fang ◽  
Xudong Sun ◽  
...  
Keyword(s):  
Hospital Stay ◽  
Aortic Regurgitation ◽  
Transcatheter Closure ◽  
Ventricular Septal Defects ◽  
Residual Shunt ◽  
Septal Defects ◽  
Device Implantation ◽  
Limited Experience ◽  
New Onset

AbstractBackground:There is limited experience about transcatheter closure of doubly committed subarterial ventricular septal defects with Amplatzer ductal occluder.Methods:Between March, 2015 and July, 2017, a total of 22 patients with doubly committed subarterial ventricular septal defects received transcatheter closure using Amplatzer ductal occluder and underwent clinical follow-up for at least 6 months.Results:Device implantation was finally successful in 21 (95.4%) patients despite failed occlusion in one patient and intra-procedural replacement of unsuitable occluders in four (19.0%) patients. In mean 12.3 months of follow-up, there were no major complications (death, aortic valve or sinus rupture, device dislocation or embolisation, grade 2 new-onset aortic regurgitation, etc.), resulting in clinical occlusion success of 95.4%. Mechanical haemolysis occurred in one patient and resolved with medication. Residual shunt was observed in 11 (52.4%) patients (9 mild, 2 moderate-severe) post-procedurally, 14 (66.7%) patients (12 mild, 2 moderate-severe) in hospital stay, and 2 (9.5%) patients (2 mild, 0 moderate-severe) at the last follow-up. Device-induced new-onset aortic regurgitation was found in nine (42.8%) patients (9 mild, 0 moderate-severe) post-procedurally and in hospital stay, which was resolved in two (9.5%) patients and unchanged in seven (33.3%) patients at the last follow-up. Another four (19.0%) patients newly developed mild aortic regurgitation during follow-up.Conclusions:Transcatheter closure of doubly committed subarterial ventricular septal defects with Amplatzer ductal occluder is technically feasible in the selected patients. However, further study is needed to confirm its long-term clinical outcomes.

scholarly journals Short- and medium-term follow-up of transcatheter closure of perimembranous ventricular septal defects

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Hao Li ◽  
Youyang Shi ◽  
Songyue Zhang ◽  
Yue Ren ◽  
Xing Rong ◽  
...  
Keyword(s):  
Transcatheter Closure ◽  
Interventional Cardiology ◽  
Ventricular Septal Defects ◽  
Tricuspid Valve Regurgitation ◽  
Serious Adverse Event ◽  
Septal Defects ◽  
Device Implantation ◽  
Mean Size ◽  
The Mean

Abstract Background Transcatheter closure of perimembranous ventricular septal defects is one of the greatest challenges in interventional cardiology. Short- and midium-term follow-up data for large samples are limited. This report presents our experience with transcatheter closure of perimembranous ventricular septal defects using an occluder. Methods Two hundred fifty-three patients included in the database of the Second Affiliated Hospital and Yuying Children’s Hospital from January 2011– December 2015 with transcatheter closure of perimembranous ventricular septal defects and discharged from follow-up. All patients were invited for clinical and transthoracic echocardiography, electrocardiogram, and thoracic radiography check-up. Results Device implantation was successful in 252 of 253 patients (99.6%). The median age was 42 months (range 27–216 months). The median follow-up duration was 36 months (range 6–60 months). The mean defect diameter was 3.5 ± 1.4 mm and the mean size of the ventricular septal defect rim below the aortic valve was 3.7 ± 1.8 mm. The mean diameter of the devices used was 4 mm. Thirty-seven patients developed arrhythmia after the procedure and recovered within 24 months; four patients had hemolysis and four had moderate tricuspid valve regurgitation. No other serious adverse event occurred during the follow-up period. Conclusion Transcatheter closure of perimembranous ventricular septal defects using an occluder is safe and effective in most patients.

Surgical Management of Ventricular Septal Defects and Mitral Regurgitation Complicating Acute Myocardial Infarction

1973 ◽  
Vol 16 (6) ◽  
pp. 598-609 ◽  
Author(s):  
Mortimer J. Buckley ◽  
Eldred D. Mundth ◽  
Willard M. Daggett ◽  
Herman K. Gold ◽  
Robert C. Leinbach ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Mitral Regurgitation ◽  
Surgical Management ◽  
Ventricular Septal Defects ◽  
Septal Defects

scholarly journals In-Hospital Outcomes and Long-Term Follow-Up after Percutaneous Transcatheter Closure of Postinfarction Ventricular Septal Defects

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Ruoxi Zhang ◽  
Yong Sun ◽  
Meng Sun ◽  
Hui Zhang ◽  
Jingbo Hou ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Blood Pressure ◽  
Acute Myocardial Infarction ◽  
Left Ventricular Ejection ◽  
Ventricular Septal Defects ◽  
Survival Group ◽  
Septal Defects ◽  
Interventional Closure ◽  
Death Group

Postinfarction ventricular septal defects (VSD) represent a devastating complication of acute myocardial infarction and are associated with high mortality. Percutaneous interventional closure of postinfarction VSD has been proposed as a potential alternative to surgery. The study aimed to evaluate the therapeutic safety and efficacy of percutaneous interventional closure of postinfarction ventricular septal defects (VSD). Each patient was assigned to one of two groups, based on whether they died during hospitalization (death group) or survived (survival group) in this retrospective study. In-hospital and follow-up data were analyzed. Placement of the VSD occluder was successful in 12 procedures (80%). The mean defect size was 14.20 ± 4.89 mm. Compared to the patients who died, those who survived had higher systolic blood pressure, diastolic blood pressure, and left ventricular ejection fraction upon admission, as well as lower pulmonary/systemic flow ratio and shorter time from acute myocardial infarction to procedure. The incidence of cardiac shock and class IV heart failure was lower in the survival group than in the death group, and these factors correlated with in-hospital and 30-day mortality. Percutaneous closure of postinfarction VSD is an effective technique, which can be performed with a high procedural success rate.

Sign in / Sign up

Export Citation Format

Share Document